**The Gavin R. Stevens Foundation and**

**The Foundation Fighting Blindness**

**Research Summary**

**Project Title:** Gene Therapy for *NMNAT1* LCA

**Investigators:**  Dr. Eric Pierce, Dr. Luk Vandenberghe

 Ocular Genomics Institute, Mass Eye and Ear and Harvard Medical School

**Period of Support:** 2013 to 2016

**1. Background**

In 2011 several research groups reported that mutations in the *NMNAT1* gene cause Leber congenital amaurosis (LCA), accounting for about 5% of cases ([1-5](#_ENREF_1)). LCA is an early onset form of inherited retinal degeneration (IRD). Affected children have reduced vision and nystagmus (involuntary eye movements).

The finding that mutations in *NMNAT1* cause LCA is of interest for several reasons. First, it provides a target for efforts to develop treatments for IRDs, such as gene therapies. Second, it raises some interesting questions about retinal biology, the answers to which we hope will inform our efforts to develop treatment(s) for this form of retinal degeneration. For example, the *NMNAT1* gene encodes an enzyme that is needed for synthesis of nicotinamide adenine dinucleotide (NAD) inside cells. NAD has multiple important roles in cell function, including helping capture energy from nutrients, and regulation of the function of several types of proteins. As a reflection of the importance of NAD in cell function, there are three versions NMNAT in cells; NMNAT1 is located specifically in the nuclei of cells ([6](#_ENREF_6)). Since NAD is needed in the nuclei of all cells, it is not clear why mutations in *NMNAT1* affect the retina but not other parts of the body.

Data from studies performed to date suggest that the retinal disease which results from mutations in the *NMNAT1* gene is caused by reduction NAD production by NMNAT1 in the nuclei of retinal cells. Unfortunately, the other versions of NMNAT, called NMNAT2 and 3, cannot compensate for the loss of NMNAT1 function ([7](#_ENREF_7)). The goal of our research is to test the idea that restoration of NMNAT1 function to normal levels via gene augmentation therapy can be beneficial for patients affected by *NMNAT1*-associated retinal degeneration.

**2. Research Program**

A. *Nmnat1* Mutant Mice

In order to test the use of gene therapy for treating NMNAT1-associated retinal degeneration, we first had to identify a model system to use for our research studies. Through collaborations with Dr. Mike Bowl from the Medical Research Council (MRC) center for mouse genetics in Harwell, England and Patsy Nishina at the Jackson Labs in Maine, we have identified and characterized two different mouse models of NMNAT1-associated disease.

First, with Mike Bowl’s help, we identified mice with a mutation in NMNAT1 that changes the 9th amino acid in the protein from Valine to Methionine. This mutation is abbreviated as Val9Met, and has been found in several patients affected by *NMNAT1*-associated LCA. Like the patients, the *Nmnat1*-Val9Met mice experience rapid retinal degeneration, with reduction of retinal function and loss of retinal cells detected within 4 months. These data suggest that the light sensitive or photoreceptor cells of the retina are the first cells to be affected to reduced NMNAT1 function ([8](#_ENREF_8)).

Second, investigators in Patsy Nishina’a lab found mice with an Asp243Gly mutation in NMNAT1. The Asp243Gly mutation has not yet been identified in patients with retinal degeneration. These mice also have retinal disease, with a slower rate of degeneration than the Val9Met mice ([8](#_ENREF_8)).

B. NMNAT1 Gene Therapy

With good models of *NMNAT1*-associated disease in hand, we are now working on developing gene augmentation therapy for *NMNAT1*. For these studies, we are using delivery vectors derived from Adeno-Associated Virus (AAV). AAV is the gene delivery system that is being used in multiple other gene therapy studies, including the clinical trials of gene therapy for *RPE65*-associated retinal degeneration and CHM-associated retinal degeneration (choroideremia) ([9-15](#_ENREF_9)). .

Unlike the *RPE65* and *CHM* studies in which the therapeutic gene needs to be delivered to the retinal pigment epithelial (RPE) cells of the retina, we need to use AAV to deliver NMNAT1 to the light sensitive or photoreceptor cells of the retina. We are fortunate to be doing these studies in collaboration with Dr. Luk Vandenberghe, an expert in the use of AAV for gene therapy.

For these studies, we are making and testing several AAV vector systems for *NMNAT1*. The elements we are evaluating include different promoters, which drive the expression of the therapeutic *NMNAT1* gene in retinal cells and different vector serotypes, which modulate the types of cells infected by the viruses. All the AAV vectors we are testing have been made with a synthetic human *NMNAT1* gene that can be used in future human studies. Vector preparations are generated and purified in the Ocular Gene Transfer Core Facility of the OGI using established techniques ([16](#_ENREF_16),[17](#_ENREF_17)).

**3. Summary**

We are hopeful that the ongoing studies will provide evidence that gene augmentation therapy for *NMNAT1*-associated retinal degeneration can be beneficial. Our goal is to identify the best gene therapy approach to bring forward towards human clinical trials. If our initial attempts at gene therapy in the *Nmnat1* mutant mice are not successful, we are hopeful that improved understanding of the mechanism by which mutations in *NMNAT1* lead to retinal degeneration will help us identify additional approaches which can ultimately be used for treating patients with this form of LCA.

**References**

1. den Hollander AI, Black A, Bennett J, Cremers FP.Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. *Journal Clinical Investigation*. 2010;120:3042-53. PMCID: 2929718.

2. Falk MJ, Zhang Q, Nakamaru-Ogiso E, Kannabiran C, Fonseca-Kelly Z, Chakarova C, Audo I, Mackay DS, Zeitz C, Borman AD, Staniszewska M, Shukla R, Palavalli L, Mohand-Said S, Waseem NH, Jalali S, Perin JC, Place E, Ostrovsky J, Xiao R, Bhattacharya SS, Consugar M, Webster AR, Sahel JA, Moore AT, Berson EL, Liu Q, Gai X, Pierce EA.NMNAT1 mutations cause Leber congenital amaurosis. *Nature Genetics*. 2012;44:1040-5.

3. Koenekoop RK, Wang H, Majewski J, Wang X, Lopez I, Ren H, Chen Y, Li Y, Fishman GA, Genead M, Schwartzentruber J, Solanki N, Traboulsi EI, Cheng J, Logan CV, McKibbin M, Hayward BE, Parry DA, Johnson CA, Nageeb M, Poulter JA, Mohamed MD, Jafri H, Rashid Y, Taylor GR, Keser V, Mardon G, Xu H, Inglehearn CF, Fu Q, Toomes C, Chen R.Mutations in NMNAT1 cause Leber congenital amaurosis and identify a new disease pathway for retinal degeneration. *Nature Genetics*. 2012;44:1035-9.

4. Chiang PW, Wang J, Chen Y, Fu Q, Zhong J, Yi X, Wu R, Gan H, Shi Y, Barnett C, Wheaton D, Day M, Sutherland J, Heon E, Weleber RG, Gabriel LA, Cong P, Chuang K, Ye S, Sallum JM, Qi M.Exome sequencing identifies NMNAT1 mutations as a cause of Leber congenital amaurosis. *Nature Genetics*. 2012;44:972-4.

5. Perrault I, Hanein S, Zanlonghi X, Serre V, Nicouleau M, Defoort-Delhemmes S, Delphin N, Fares-Taie L, Gerber S, Xerri O, Edelson C, Goldenberg A, Duncombe A, Le Meur G, Hamel C, Silva E, Nitschke P, Calvas P, Munnich A, Roche O, Dollfus H, Kaplan J, Rozet JM.Mutations in NMNAT1 cause Leber congenital amaurosis with early-onset severe macular and optic atrophy. *Nature Genetics*. 2012;44:975-7.

6. Lau C, Niere M, Ziegler M.The NMN/NaMN adenylyltransferase (NMNAT) protein family. *Frontiers in bioscience : a journal and virtual library*. 2009;14:410-31.

7. Conforti L, Janeckova L, Wagner D, Mazzola F, Cialabrini L, Di Stefano M, Orsomando G, Magni G, Bendotti C, Smyth N, Coleman M.Reducing expression of NAD+ synthesizing enzyme NMNAT1 does not affect the rate of Wallerian degeneration. *The FEBS Journal*. 2011;278:2666-79.

8. Greenwald SH, Charette JR, Staniszewska M, Shi LY, Brown SD, Stone L, Liu Q, Hicks WL, Collin GB, Bowl MR, Krebs MP, Nishina PM, Pierce EA.Mouse Models of NMNAT1-Leber Congenital Amaurosis (LCA9) Recapitulate Key Features of the Human Disease. *Am J Pathol*. 2016.

9. Maguire AM, Simonelli F, Pierce EA, Pugh EN, Jr., Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell'Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J.Safety and efficacy of gene transfer for Leber's congenital amaurosis. *New England Journal of Medicine*. 2008;358:2240-8. PMCID: 2829748.

10. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR.Effect of gene therapy on visual function in Leber's congenital amaurosis. *New England Journal of Medicine*. 2008;358:2231-9.

11. Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, Pang JJ, Sumaroka A, Windsor EA, Wilson JM, Flotte TR, Fishman GA, Heon E, Stone EM, Byrne BJ, Jacobson SG, Hauswirth WW.Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. *Proceedings National Academy Sciences USA*. 2008;105:15112-7. PMCID: 2567501.

12. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, Mingozzi F, Bennicelli JL, Ying GS, Rossi S, Fulton A, Marshall KA, Banfi S, Chung DC, Morgan JI, Hauck B, Zelenaia O, Zhu X, Raffini L, Coppieters F, De Baere E, Shindler KS, Volpe NJ, Surace EM, Acerra C, Lyubarsky A, Redmond TM, Stone E, Sun J, McDonnell JW, Leroy BP, Simonelli F, Bennett J.Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. *Lancet*. 2009;374:1597-605.

13. Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, Roman AJ, Peden MC, Aleman TS, Boye SL, Sumaroka A, Conlon TJ, Calcedo R, Pang JJ, Erger KE, Olivares MB, Mullins CL, Swider M, Kaushal S, Feuer WJ, Iannaccone A, Fishman GA, Stone EM, Byrne BJ, Hauswirth WW.Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. *Archives Ophthalmology*. 2012;130:9-24.

14. Bennett J, Ashtari M, Wellman J, Marshall KA, Cyckowski LL, Chung DC, McCague S, Pierce EA, Chen Y, Bennicelli JL, Zhu X, Ying GS, Sun J, Wright JF, Auricchio A, Simonelli F, Shindler KS, Mingozzi F, High KA, Maguire AM.AAV2 gene therapy readministration in three adults with congenital blindness. *Science Translational Medicine*. 2012;4:120ra15.

15. MacLaren RE, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, Seymour L, Clark KR, During MJ, Cremers FP, Black GC, Lotery AJ, Downes SM, Webster AR, Seabra MC.Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. *Lancet*. 2014;383:1129-37.

16. Lock M, Alvira M, Vandenberghe LH, Samanta A, Toelen J, Debyser Z, Wilson JM.Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. *Human Gene Therapy*. 2010;21:1259-71. PMCID: 2957274.

17. Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R, Wang L, Castle MJ, Maguire AC, Grant R, Wolfe JH, Wilson JM, Bennett J.Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. *Science Translational Medicine*. 2011;3:88ra54.